Id: acc3613
Group: 2sens_supp
Protein: IkappaBalpha
Gene Symbol: NFKBIA
Protein Id: P25963
Protein Name: IKBA_HUMAN
PTM: phosphorylation
Site: Ser32
Site Sequence: ERLLDDRHDSGLDSMKDEEYE
Disease Category: Cancer
Disease: Leukemia
Disease Subtype:
Disease Cellline: KBM–5
Disease Info:
Drug: taxol
Drug Info: Taxol is an anti - cancer drug commonly used in the treatment of various cancers. It can inhibit the growth of cancer cells.
Effect: inhibit
Effect Info: Indirubin enhances TNF- and chemotherapeutic drug paclitaxel-induced apoptosis.
Note:
Score: 5.0
Pubmed(PMID): 16785236
Sentence Index:
Sentence:

Sequence & Structure:

MFQAAERPQEWAMEGPRDGLKKERLLDDRHDSGLDSMKDEEYEQMVKELQEIRLEPQEVPRGSEPWKQQLTEDGDSFLHLAIIHEEKALTMEVIRQVKGDLAFLNFQNNLQQTPLHLAVITNQPEIAEALLGAGCDPELRDFRGNTPLHLACEQGCLASVGVLTQSCTTPHLHSILKATNYNGHTCLHLASIHGYLGIVELLVSLGADVNAQEPCNGRTALHLAVDLQNPDLVSLLLKCGADVNRVTYQGYSPYQLTWGRPSTRIQQQLGQLTLENLQMLPESEDEESYDTESEFTEFTEDELPYDDCVFGGQRLTL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
NFKBIA-Ser32
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 32 U Head and neck squamous cell carcinoma Phosphorylation 21281788
T 32 U Head and neck squamous cell carcinoma Phosphorylation 21281788

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: